

EndoVenous Ablation: **for** PUBLIC

Winnipeg Vascular Symposium
Apr 4, 2025

G. Sarwal, MD MEd FRCSC (VSx) CAiR (fellow)
Cardiac & Vascular Interventionalist

St. Paul's Hospital
Vancouver, BC



THE UNIVERSITY OF BRITISH COLUMBIA

Disclosures

I have the following relationships with commercial interests:

- **Grants & Research support:** none
- **Travel stipends:** BD Bard, Shockwave, Cook, Penumbra, Inari, Abiomed & Getinge
- **Honoraria:** BD Bard, Terumo, Boston Scientific, Bentley Innomed & Sigvaris
- **Consultant:** Total Flow Medical (ECMO cannulas)



THE UNIVERSITY OF BRITISH COLUMBIA

Dr. Jerry Chen, Inc

- Ex-pi
- Phen
- Strong
 - Pitts



YOUR NAME
Your Address

VALID FOR SIX MONTH ONLY

D	D	M	M	Y	Y	Y	Y		

Pay

Dollars

\$

AUTHORIZED SIGNATURE

utterstock.com - 231773500

\$x

teacher

d

Varicose Veins

Treatment goal:

- Eliminate reflux
- Reduce symptoms
- Minimize recurrence
- Improve QoL
- Avoid long-term complications

Treatment options:

- EVA or ligation/stripping +/- sclerotherapy




Vein stripping

...why are we *still* talking about this?



Vein Stripping



Vein stripping

Increased rates of recurrence


- 33% at 2 years, 50-70% at 10 years

Increased complications

- Nerve injury
- Infection
- Hematoma
- Scarring
- Lymph leakage

Prolonged recovery


Early return to hospital (20%)



EndoVenous Ablation (RFA)

- **Setting:** angio suite or OR
- **Anaesthesia:** local with mild sedation
- Non-invasive
- Insignificant recovery period
- Minimal patient preparation
- Safe & effective
- Low risk of infection, scarring & nerve injury





“The way we work in public health is, we make the best recommendations and decisions based on the best available data”

Tom Frieden

Facts: EVLA is safe



Table C.1: Evidence from systematic reviews/meta-analyses

Study	Methods	Results	Authors' conclusions
Lynch et al. 2015 ² SR/MA	Search date: various databases from inception until 31 Oct 2013 Study selection criteria:	No. of included studies: 9 reports of 6 RCTs with a total of 1,289 limbs. Recurrence: comparable between the two groups in the relatively short follow-up period. MA revealed a trend towards a	EVLA is a safe alternative to traditional open surgery. There is some weak evidence to suggest that EVLA has a higher detected months compared to however, it may have less sensory deafferentation,
Nesbitt et al. 2014 ¹⁷ SR/MA	and associated complications • Study design: RCTs Quality assessment: Cochrane risk of bias tool	and late recanalisation. Neovascularisation and technical failure were both statistically reduced in the EVLA group ($P < .0001$ and $P = .0009$, respectively). Long-term (5-year) outcomes were evaluated in one study, no association could be derived, but it appeared that EVLA and surgery maintained similar findings. • RFA vs. surgery: no differences in clinician noted recurrence; symptomatic noted recurrence was only evaluated in a single study. No differences for	the clinical trial results that FS, were at least as early in the saphenous due to large between trials point for outcomes, checking in other RCTs are could aim to the results in a congruent manner to facilitate future meta-analysis.



THE UNIVERSITY OF BRITISH COLUMBIA

Facts



ed studies: 10 RCTs and 3 non-randomized trials with a total of 2,245 limbs.

ical success rates: difference in initial technical success rates was not significant (P=.13). Procedural failures were more common following

EVLA for varicose veins is safe and effective compared with surgery in a 2-year range. More randomized controlled studies



anesthesia rate was significantly lower with EVLA vs. RFA (P=.001) and surgery (P<.001). The rate of thrombophlebitis was significantly lower for surgery vs. RFA (P=.003) and EVLA (P=.003). No difference in the rate of thermal skin burns between EVLA and surgery.

a significantly lower rate of paraesthesia as compared with RFA and surgery. Thermal skin burns occur with equal frequency in RFA and EVLA.



THE UNIVERSITY OF BRITISH COLUMBIA

Financial data

Economic implications of endovenous great saphenous ablation in a public health care system

[Abdalla Butt](#)^a · [David Kopriva, MDCM, FRCS\(C\)](#) ^{b,c} 

Methods: retrospective review of EVA vs stripping 2003-14

Results:

- rates of EVA remained consistent pre & post public funding
- Case costs of stripping (\$1965) > EVA (RFA: \$1410)
- Total annual costs of GSV intervention decreased from \$176k to \$134k

Conclusions: introduction of public-funded EVA reduced global health spending by \$42000, without increasing GSV intervention rate

Financial data

Table C.2: Evidence from HTAs

Study	Method	Results	Authors' conclusions
<p>Brittenden et al. 2015¹⁰</p> <p>RCT and economic modelling evaluation</p>	<p>Search date: up to 2013</p> <p>Assessment was primarily based on the CLASS trial):</p> <ul style="list-style-type: none"> Population: 798 patients with varicose veins from 11 UK vascular centres Intervention: FS (n=292), Comparator: surgery (n=292) Outcome measures: <ul style="list-style-type: none"> Primary: QoL: Disease-specific (AVVQ) and generic (EQ-VAS) at 6 months and cost-effectiveness (cost per QALY gained) Secondary: QoL at 6 months, varicose veins, VCSS rates, return to normal vein ablation rates, and Study design: A parallel-group, randomised, without blinding, and economic evaluation <p>Quality assessment: NR</p>	<p>No. of included studies: 9 RCTs that compared EVLA to open surgery, or FS.</p> <p>with FS was similar to that of surgery. The mean score for FS was similar to that for surgery. Component scores in the trials were greater for EVLA (1%) than after FS than following surgery and EVLA (P<.001)</p> <p>at 6 months, FS was effective at a ceiling willingness-to-pay ratio of 20,000 per QALY. EVLA was found to cost \$26,107 per QALY gained vs. FS, and was less costly and generated slightly more QALYs than surgery. Markov modelling using trial costs and the limited recurrence data available suggested that, at 5 years, EVLA had the highest probability (79%) of being cost-effective at conventional thresholds, followed by FS (17%) and surgery (5%).</p>	<p>Considerations of both the 6-month clinical outcomes and the estimated 5-year cost-effectiveness suggest that EVLA should be considered as the treatment of choice for suitable patients.</p>



Standard of care



THE UNIVERSITY OF BRITISH COLUMBIA

Vancouver Housing Market: Apr. 3rd, 2025 Update - WOWA.ca

The average home price in Greater Vancouver was \$1,239,418, which decreased by 5.9% annually and climbed by 1.2%...

 WOWA.ca



British Columbia

Rundown Vancouver house for \$2.4M: Ridiculous or a bargain?

New house nearby sells for almost double the price

[Lien Yeung](#) · CBC News · Posted: Jan 29, 2016 9:18 PM CST | Last Updated: January 30, 2016



Both these houses are listed for sale in the Vancouver neighbourhood of Point Grey. The old home on the left is priced at nearly \$2.4M, the brand new one on the right for \$4.3M.

Clinical Practice Guidelines

Table C.3: Summary of CPGs and recommendation reports

Study	Method	Recommendations
Wittens 2015 ¹² European Society for Vascular Surgery (ESVS)	Systematic literature search up to Jan 2013 Grading: using the European Society of Cardiology grading system (level of evidence A, B, C, and classes of recommendation I, II< and III) CPGs developed by ESVS, IUP made comments on all recommendations	<p><u>For the treatment of GSV reflux in patients with symptoms and signs of chronic venous disease:</u></p> <ul style="list-style-type: none"> • EVTA techniques are recommended in preference to surgery (Level A) • EVTA techniques are recommended in preference to FS (Level A) <p><u>For the treatment of SSV reflux in patients with symptoms and signs of chronic venous disease:</u></p> <ul style="list-style-type: none"> • EVTA should be considered (Level B)
O'Donnell et al. 2014 ²³ Society of Vascular Surgery and American Venous Forum	Guidelines developed by building on existing guidelines with a complementary literature search Quality of evidence and strength of recommendations were scored according to GRADE system	<p><u>For superficial venous reflux and active venous leg ulcer:</u></p> <ul style="list-style-type: none"> • suggest ablation of the incompetent veins in addition to standard compressive therapy to improve ulcer healing (GRADE 2, Level of evidence C) • recommend ablation of the incompetent veins in addition to standard compressive therapy to prevent recurrence (GRADE 1, Level of evidence B) <p><u>For superficial venous reflux and healed venous leg ulcer:</u></p> <ul style="list-style-type: none"> • recommend ablation of the incompetent veins in addition to standard compressive therapy to prevent recurrence (GRADE 1, Level of evidence C) <p><u>For superficial venous reflux with skin changes at risk for venous leg ulcer:</u></p> <ul style="list-style-type: none"> • suggest ablation of the incompetent superficial veins in addition to standard compressive therapy to prevent ulceration (GRADE 1, Level of evidence C) <p><u>For combined superficial and perforator venous reflux with or without deep venous reflux and active venous leg ulcer:</u></p> <ul style="list-style-type: none"> • suggest ablation of both the incompetent superficial veins and perforator veins in addition to standard compressive therapy to aid in ulcer healing and to prevent recurrence (GRADE 2, Level of evidence C) <p><u>For combined superficial and perforator venous reflux with or without deep venous disease and skin changes at risk for venous leg ulcer or healed venous ulcer:</u></p> <ul style="list-style-type: none"> • suggest ablation of the incompetent superficial veins to prevent the development or recurrence of a venous leg ulcer (GRADE 2, Level of evidence C) <p><u>For pathologic perforator venous reflux in the absence of superficial venous disease, with or without deep venous reflux, and a healed or active venous ulcer:</u></p> <ul style="list-style-type: none"> • suggest ablation of the "pathologic" perforating veins in addition to standard compression therapy to aid in venous ulcer healing and to prevent recurrence (GRADE 2, Level of evidence C)

Summary

- **EVA** is safe, effective & cheaper with shorter patient recovery time
- **Standard of care** for addressing superficial venous reflux
- Role still exists for private pay in cosmetic patients





G. Sarwal, MD MEd FRCSC (VSx) CAiR (fellow)
Cardiac & Vascular Interventionalist

gautamn.sarwal@gmail.com
St. Paul's Hospital
Vancouver, BC

EVA Ablation REBUTTAL: **for** PUBLIC

Winnipeg Vascular Symposium
Apr 4, 2025



THE UNIVERSITY OF BRITISH COLUMBIA

Role for vein stripping



shutterstock.com • 780486985

EndoVenous Ablation

VENOCARE DUBAI

1/3



**DID YOU
KNOW?**

**EVL is the Gold Standard for
Varicose Vein Treatment!**

@VenocareDubai



- EVA is the gold standard for addressing venous reflux for both patients & HCPs
- The question that I challenge you with:

Would you refer/recommend/inform patients to centers that offer public RFA?